Given that these fusion partners are all FET family members, seclidemstat, as previously mentioned in myxoid liposarcoma harboring EWSR1/FUS–DDIT3 chromosomal translocations, may have promising effects in extraskeletal myxoid chondrosarcoma, considering that seclidemstat, an LSD1 inhibitor, can block transcription of fusions involving FET family members (NCT03600649). This evidence concerns the gene EWSR1 and myxoid liposarcoma.